Tech Transfer Doesn’t Have to Take Months. Here’s What’s Actually Broken.

Ask anyone who has moved a process from development into clinical or commercial manufacturing, and you’ll hear the same story: months of delay, mountains of paperwork, and no small amount of risk, all to get a process that already works in the lab to work comparably on the plant floor.

We’ve come to accept this as the cost of doing business in life sciences. It shouldn’t be.

CMC sits at the narrowest point in the drug development lifecycle. It’s where a molecule stops being a research problem and becomes a manufacturing one, and where timelines quickly balloon. This is often a natural outcome of working at the cutting edge of science, but more often it happens because information about that science doesn’t travel well.

Process parameters live in one system. Batch records live in another—often paper. Methods get re-typed, not transferred. Every handoff between development, clinical manufacturing, and commercial scale becomes an opportunity for a transcription error, a validation delay, or a data integrity question nobody wants to answer during an audit.

None of this is a failure of the people involved. It’s a failure of treating process knowledge as a document instead of what it is: data.

What if a recipe wasn’t a PDF, Word, or Excel document but a structured, versioned digital object in much the same way as source code?

When process parameters and manufacturing recipes are structured data rather than documents, they no longer need to be manually re-entered at every stage. Design-space data can inherit directly into master batch records. Master batch records can inherit directly into shop-floor execution. The same digital object can be orchestrated across multiple sites, automatically configured for each site’s equipment, without anyone retyping a single value.

This is already possible, and it fundamentally changes a trade-off most of us have stopped questioning. Historically, “faster” has meant assuming more risk or locking suboptimal processes to save time. Digital tech transfer breaks that trade-off by enabling continuous data lineage from lab to plant, thereby making a transfer both faster and more auditable, rather than trading one at the expense of the other.

Most organizations are neither starting from zero nor starting from “solved”. The majority sit somewhere in between, with some processes still on paper while others have partial digital syncing stitched together through custom data stores. Very few have reached a genuinely unified data model where information flows bidirectionally between lab and plant in real time.

It’s worth acknowledging the current state of digital maturity because the gap between “digital silos” and a truly connected, predictive operation is exactly where the next few years of competitive advantage will be won or lost. The organizations that close that gap will move faster, and they will have better data, fewer deviations, and an easier time proving it to a regulator.

Beyond the near-term gains in speed and audit-readiness, there is a longer-term reason to get this right. L7 takes its name from Level 7, the top of the Industry 4.0 maturity model, where each level is foundational to the one above it. The sequencing matters.

While I share the enthusiasm for applying intelligent systems to pharmaceutical operations, the value of anything built on top is bounded by the connectedness of the data underneath. An organization with six disconnected systems and a manual transfer process does not have an AI problem. It has a data foundation problem, and nothing layered above will reach down and fix it.

Tech transfer is simply where the absence of that foundation costs the most, and where it falls hardest on the people doing the work. That is reason enough to take it on.

—

FAQs